Skip to main
VKTX

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics (VKTX) Analyst Ratings

Based on 7 analyst ratings
Strong Buy
Strong Buy 57%
Buy 43%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Viking Therapeutics is positioned to develop best-in-class therapies for metabolic disorders with its highly differentiated GLP-1/GIP asset VK2735 in both subcutaneous and oral formulations likely to be favored by patients and physicians, and its lead TRβ compound VK2809 expected to excel against competitors in both potency and tolerability. With positive trial outcomes and a strong commercialization strategy, Viking Therapeutics has the potential for significant market share and growth, making it a positive stock pick for investors.

Bears say

Viking Therapeutics is heavily reliant on milestone payments and royalties, making it highly susceptible to delays in reaching development, regulatory, and sales milestones. Additionally, Viking's future success is dependent on its Phase 1 maintenance study and the potential incorporation of a maintenance component into future studies, creating uncertainty and potential for delays and setbacks. The company's single molecule, multi-format approach may provide some competitive advantage, but it is not a guarantee for success in a highly competitive and evolving obesity market.

Viking Therapeutics (VKTX) has been analyzed by 7 analysts, with a consensus rating of Strong Buy. 57% of analysts recommend a Strong Buy, 43% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viking Therapeutics (VKTX) Forecast

Analysts have given Viking Therapeutics (VKTX) a Strong Buy based on their latest research and market trends.

According to 7 analysts, Viking Therapeutics (VKTX) has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $101, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $101, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viking Therapeutics (VKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.